Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma

Nivolumab plus ipilimumab (nivo + ipi) is a standard treatment of advanced melanoma. Two randomized trials describe high objective response rates by Response Evaluation Criteria in Solid Tumors. The trials assessed toxic effects using the Common Terminology Criteria for Adverse Events (CTCAE), which...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	JAMA oncology Ročník 4; číslo 1; s. 98
Hlavní autori:	Shoushtari, Alexander N, Friedman, Claire F, Navid-Azarbaijani, Pedram, Postow, Michael A, Callahan, Margaret K, Momtaz, Parisa, Panageas, Katherine S, Wolchok, Jedd D, Chapman, Paul B
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 01.01.2018
Predmet:	Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use Compassionate Use Trials Disease Progression Disease-Free Survival Drug-Related Side Effects and Adverse Reactions - epidemiology Female Humans Incidence Ipilimumab - administration & dosage Ipilimumab - adverse effects Male Melanoma - drug therapy Melanoma - epidemiology Melanoma - pathology Middle Aged Nivolumab - administration & dosage Nivolumab - adverse effects Prospective Studies Skin Neoplasms - drug therapy Skin Neoplasms - epidemiology Skin Neoplasms - pathology Time Factors Treatment Failure Young Adult
ISSN:	2374-2445, 2374-2445
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!